United Kingdom Archives

f2g fungal infections antifungals aspergillosis

News and Trends 22 Jun 2016

Massive Round: Novel Antifungals get €53M from Top-Notch Investors

F2G has raised €53M to advance its news class of treatments for life-threatening fungal infections, including invasive aspergillosis. The technology has attracted some of the major biotech investors in Europe. Based in Manchester (UK), F2G focuses on developing therapies for invasive fungal infections such as aspergillosis. This type of infections mostly affect patients that are […]

June 22, 2016 - 2 minutesmins - By Denise Neves Gameiro

circassia cat grass allergy toleromune spire

News and Trends 21 Jun 2016

Allergy Immunotherapy Knocked Out in Phase III by an ‘Overperforming Placebo’

Circassia’s pipeline takes a major step back as its therapy for cat allergy gets disappointing results — it had the same effect as the placebo. Stocks promptly sank by 65%. The Oxford-based Circassia has been a major European player in the field of allergy immunotherapies. It made a splash when it raised €267.7M in the London Stock […]

June 21, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 17 Jun 2016

Effective anti-infectives for medically unmet diseases? Ask Novabiotics

Toulouse was fun, but it’s time to go somewhere new! Fan of the Highlands, the landscapes that made the Harry Potter scenery much more exciting and the Loch Ness Monster? I’m just asking because this week we are going to Scotland! Aberdeen is our final destination, and we are visiting Novabiotics, our Biotech of the […]

June 17, 2016 - 2 minutesmins - By Joachim Eeckhout

eva daignostics startup battle labiotech refresh biotech

News and Trends 15 Jun 2016

Eva Diagnostics: “We identified the pain points of the Blood testing market” #LBRefresh

Eva Diagnostics was one of the contestants at our Startup Battle during Labiotech Refresh. Take a second look with us at the pitch of Eva’s exciting diagnostic Tech… We had Sabine Dziemian, the head of data analysis at Eva Diagnostics, explain how this spin-off out of Imperial College London is joining the race for MedTech diagnostics. […]

June 15, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 15 Jun 2016

Boosting a Single Protein makes for a 50% more Productive Rice

Researchers from the John Innes Centre and Nanjing Agricultural University have identified a protein that can help plants regulate their cell pH – a seemingly small modification that can boost rice crop yields by 50%. Rice is one of the major crops in the world, along with corn and wheat (also under the microscope of science […]

June 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

ziarco atopic dermatitis psoriasis skin inflammation

News and Trends 14 Jun 2016

British Biotech startup shows 50% improvement in Atopic Dermatitis

Ziarco has received positive results from a Phase II trial with its leading candidate, which has shown to improve symptoms of atopic dermatitis by 50%, giving it the potential to fill the current need for a safe oral treatment for this inflammatory skin disease. Ziarco is a private biotech with a clinical-stage pipeline for inflammatory skin […]

June 14, 2016 - 2 minutesmins - By Denise Neves Gameiro

kings college depression biomarker diagnostic

News and Trends 14 Jun 2016

New Biomarkers could make Personalized Medicine for Depression

Researchers from King’s College London have succeeded in developing a blood test that can help choose the best treatment for depression patients – a big improvement over the current trial-and-error approach. Depression doesn’t seem to be a particularly popular indication for biotechs, unlike other nervous systems diseases that reached significant milestones in the last year. Moreover, one […]

June 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 13 Jun 2016

Immunotherapy reaches Breakthrough in eliminating HIV

Immunocore has published key results for its new preclinical candidate for HIV, ImmTAV. This TCR-based immunotherapy has succeeded in targeting T-cells where HIV infection often ‘hides’ from drugs. Just after presenting promising results from its leading candidate at ASCO 2016 (read our coverage here), Immunocore is making headlines in another area – infectious disease. The […]

June 13, 2016 - 3 minutesmins - By Denise Neves Gameiro

MiNa therapeutics rna liver disease biotech

News and Trends 2 Jun 2016

RNA therapy starts first-of-a-kind trial to treat Liver Cancer

MiNA Therapeutics is launching the first saRNA human trial of its kind – OUTREACH for patients with severe liver cancer. MiNA Therapeutics is a London based RNA specialist, developing RNA activation therapeutics that restore normal function to patients’ cells with an initial focus on severe liver cancer. The study is the first-in-human trial of a small activating RNA […]

June 2, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 2 Jun 2016

A ‘Skin Spray’ could cure Chronic Skin Wounds caused by Diabetes

Avita has initiated a trial in the UK to evaluate the potential of its ReGenerCell technology to treat diabetic foot ulcers, a skin wound that can be very hard to treat. With offices in the UK and originally from Australia, Avita Medical is developing products in tissue engineering and regenerative medicine. Its technology utilises the […]

June 2, 2016 - 2 minutesmins - By Denise Neves Gameiro

gene therapy strimvelis biotech gsk offerele ada scid child

News and Trends 1 Jun 2016

EMA approves Groundbreaking Gene Therapy for Super Rare ‘Bubble Baby’ Disease

GSK, Fondazione Telethon and Ospedale San Raffaele have announced that the EMA has approved Strimvelis for a super rare immunodeficiency disease in Children. Following 20 years of research at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Italy, this is the news patients have been waiting for. Strimvelis is the first ex vivo stem cell gene […]

June 1, 2016 - 3 minutesmins - By Dani Bancroft

circassia grass allergy peptide spire trial

News and Trends 31 May 2016

UK Immunotherapy against Grass Allergies moves on to Phase III Trials

Circassia is beginning a Phase III trial for its short-course immunotherapy for grass allergies. This common type of allergy can significantly impact the life quality of patients. Circassia is based in Oxford (UK) and was part of 2014’s record Biotech IPOs – raising a whopping €268M. It focuses on respiratory diseases, such as asthma and allergies. Its […]

May 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

Massive Round: Novel Antifungals get €53M from Top-Notch Investors

Allergy Immunotherapy Knocked Out in Phase III by an ‘Overperforming Placebo’

Effective anti-infectives for medically unmet diseases? Ask Novabiotics

Eva Diagnostics: “We identified the pain points of the Blood testing market” #LBRefresh

Boosting a Single Protein makes for a 50% more Productive Rice

British Biotech startup shows 50% improvement in Atopic Dermatitis

New Biomarkers could make Personalized Medicine for Depression

Immunotherapy reaches Breakthrough in eliminating HIV

RNA therapy starts first-of-a-kind trial to treat Liver Cancer

A ‘Skin Spray’ could cure Chronic Skin Wounds caused by Diabetes

EMA approves Groundbreaking Gene Therapy for Super Rare ‘Bubble Baby’ Disease

UK Immunotherapy against Grass Allergies moves on to Phase III Trials

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!